GILEAD SCIENCES, INC. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
GILEAD SCIENCES, INC. (GILD) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $3.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-24
- GILEAD SCIENCES, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $3.00M, a 50.00% increase from fiscal 2024.
- GILEAD SCIENCES, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $2.00M, a 84.62% decline from fiscal 2023.
- GILEAD SCIENCES, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $13.00M, a 80.88% decline from fiscal 2022.
- GILEAD SCIENCES, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $68.00M, a 3300.00% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month as first filed |
|---|---|---|
| 2025-12-31 | $3.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $2.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $13.00M 10-K · filed 2026-02-24 | |
| 2022-12-31 | $68.00M 10-K · filed 2025-02-28 | |
| 2021-12-31 | $2.00M 10-K · filed 2024-02-23 | |
| 2020-12-31 | $1.00M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $3.00M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $1.00M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $9.00M 10-K · filed 2020-02-25 | |
| 2016-12-31 | $1.00M 10-K · filed 2019-02-26 | |
| 2015-12-31 | $7.00M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $2.00M 10-K · filed 2017-02-27 | |
| 2013-12-31 | $6.00M 10-K · filed 2016-02-24 | $6.60M 10-K · filed 2014-02-25 |
| 2012-12-31 | $5.00M 10-K · filed 2015-02-25 | $5.34M 10-K · filed 2013-02-27 |
| 2011-12-31 | $3.93M 10-K · filed 2014-02-25 | -$3.93M 10-K · filed 2012-02-23 |
| 2010-12-31 | -$954.00K 10-K · filed 2013-02-27 | |
| 2009-12-31 | -$794.00K 10-K · filed 2012-02-23 | |
| 2008-12-31 | -$1.90M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |